EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparative Study of Histone Deacetylase Inhibitors for Radiation Protection Using Survival Outcomes in a Mouse Model

Yukiro Kurokawa, Shinichi Watanabe, Takaaki Yano, Noriaki Hidaka, Takumi Yamaguchi, Mamoru Tanaka

Biological and Pharmaceutical Bulletin · 2025

DOI: 10.1248/bpb.b25-00574 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Biological and Pharmaceutical Bulletin, 2025. Verfasst von Yukiro Kurokawa und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacy, Ehime University Hospital, 454 Shitsukawa, Toon, Ehime 791-0295, Japan. Hauptthemen laut MEDLINE: Histone Deacetylase Inhibitors, Radiation-Protective Agents, Radiation Injuries, Experimental. Die Arbeit nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Histone deacetylases (HDACs) regulate chromatin structure and gene expression, and their inhibition has been proposed as a radioprotective strategy. However, few studies have compared multiple HDAC inhibitors (HDACis) under identical conditions. This study evaluated the efficacy of seven HDACis in a mouse total body irradiation (TBI) model. Male ICR mice received 7.5 Gy TBI followed by a single administration of valproic acid (VPA; 300 or 600 mg/kg), sodium butyrate (NaB; 500 or 1000 mg/kg), trichostatin A (TSA; 0.5 or 1.0 mg/kg), vorinostat (10 or 50 mg/kg), panobinostat (25 or 50 mg/kg), givinostat (5 or 10 mg/kg), or entinostat (25 or 50 mg/kg). Survival was monitored for 20 d. Only VPA at 600 mg/kg significantly improved survival compared with vehicle (overall p = 0.00241; p = 0.0039 vs. vehicle), while all other HDACis showed no significant benefit. VPA's efficacy may reflect a combination of effects on DNA repair, inflammation, and redox regulation rather than HDAC inhibition alone. These findings suggest VPA to be a promising candidate for radioprotection and emphasize the need for further studies to optimize dosing and explore underlying mechanisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Histone Deacetylase InhibitorsRadiation-Protective AgentsRadiation Injuries, ExperimentalAnimalsMaleMice, Inbred ICRValproic AcidWhole-Body IrradiationMiceHydroxamic Acids

Stichwörter der Autor:innen

histone deacetylase (HDAC) inhibitorradiation mitigationsurvival ratetotal-body irradiation

Substanzen

Histone Deacetylase InhibitorsRadiation-Protective AgentsValproic AcidHydroxamic Acids

Autor:innen und Institutionen

  • Division of Pharmacy, Ehime University Hospital, 454 Shitsukawa, Toon, Ehime 791-0295, Japan.
  • Department of Clinical Pharmacy, College of Pharmaceutical Sciences, Matsuyama University, 4-2 Bunkyo-cho, Matsuyama, Ehime 790-8578, Japan.

Zitieren

APA

Kurokawa, Y., Watanabe, S., Yano, T., Hidaka, N., Yamaguchi, T., & Tanaka, M. (2025). Comparative Study of Histone Deacetylase Inhibitors for Radiation Protection Using Survival Outcomes in a Mouse Model. Biological and Pharmaceutical Bulletin. https://doi.org/10.1248/bpb.b25-00574

Vancouver

Kurokawa Y, Watanabe S, Yano T, Hidaka N, Yamaguchi T, Tanaka M. Comparative Study of Histone Deacetylase Inhibitors for Radiation Protection Using Survival Outcomes in a Mouse Model. Biological and Pharmaceutical Bulletin. 2025. doi:10.1248/bpb.b25-00574

BibTeX
@article{Kurokawa2025,
  author = {Kurokawa, Yukiro and Watanabe, Shinichi and Yano, Takaaki and Hidaka, Noriaki and Yamaguchi, Takumi and Tanaka, Mamoru},
  title = {Comparative Study of Histone Deacetylase Inhibitors for Radiation Protection Using Survival Outcomes in a Mouse Model},
  journal = {Biological and Pharmaceutical Bulletin},
  year = {2025},
  doi = {10.1248/bpb.b25-00574}
}
Kostenlos starten →